Rockefeller Capital Management’s ImmunityBio IBRX Stock Holding History

Rockefeller Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$46.2K	Buy	6,020 +4,730	+367%	+$32.4K	﹤0.01%	3319
2025 Q4	$2.55K	Hold	1,290	–	–	﹤0.01%	4261
2025 Q3	$3.17K	Buy	+1,290	New	+$3.32K	﹤0.01%	3999
2023 Q1	–	Sell	-1,540	Closed	-$7K	–	2871
2022 Q4	$7K	Hold	1,540	–	–	﹤0.01%	3225
2022 Q3	$7K	Hold	1,540	–	–	﹤0.01%	3229
2022 Q2	$5K	Hold	1,540	–	–	﹤0.01%	3449
2022 Q1	$8K	Hold	1,540	–	–	﹤0.01%	3158
2021 Q4	$9K	Sell	1,540 -8,460	-85%	-$63.6K	﹤0.01%	3022
2021 Q3	$97K	Sell	10,000 -100	-1%	-$1.1K	﹤0.01%	1872
2021 Q2	$144K	Buy	10,100 +10,000	+10,000%	+$165K	﹤0.01%	1649
2021 Q1	$2K	Hold	100	–	–	﹤0.01%	3104
2020 Q4	$1K	Sell	100 -50	-33%	-$481	﹤0.01%	2729
2020 Q3	$1K	Hold	150	–	–	﹤0.01%	2486
2020 Q2	$2K	Buy	+150	New	+$847	﹤0.01%	2328

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Rockefeller Capital Management's IBRX Position: Q1 2026 in Review

Rockefeller Capital Management increased its ImmunityBio (IBRX) stake by 367% in Q1 2026, buying an estimated $32.4K and bringing the position to 6,020 shares worth $46.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3319.

Rockefeller Capital Management first reported a position in IBRX in Q2 2020 and has held it in 14 quarters since. The position peaked at $144K in Q2 2021. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

Rockefeller Capital Management held 6,020 shares of ImmunityBio worth $46.2K as of Q1 2026.
Rockefeller Capital Management bought 4,730 ImmunityBio shares in Q1 2026, an estimated $32.4K.
ImmunityBio made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #3319 holding.
Rockefeller Capital Management first reported a position in ImmunityBio in Q2 2020 and has held it in 14 quarters since.
Rockefeller Capital Management's ImmunityBio position peaked at $144K in Q2 2021.
386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.